Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2011-04-12
2011-04-12
Padmanabhan, Sreeni (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S182000, C514S874000, C514S903000
Reexamination Certificate
active
07923440
ABSTRACT:
A method of treating or preventing an immune mediated disorder in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula:in which formula R1, R2, R3, R4independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7is a hydroxyl group; no more than 3 of R1, R2, R3, R4are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. Another aspect of the invention relates to a pharmaceutical formulation comprising the aforementioned estrogenic component, an immunotherapeutic agent and a pharmaceutically acceptable excipient.
REFERENCES:
patent: 3440320 (1969-04-01), Sackler et al.
patent: 3797494 (1974-03-01), Zaffaroni
patent: 4460372 (1984-07-01), Campbell et al.
patent: 4573996 (1986-03-01), Kwiatek et al.
patent: 4624665 (1986-11-01), Nuwayser
patent: 4722941 (1988-02-01), Eckert et al.
patent: 4762717 (1988-08-01), Crowley, Jr.
patent: 4937238 (1990-06-01), Lemon
patent: 5063507 (1991-11-01), Lindsey et al.
patent: 5130137 (1992-07-01), Crowley, Jr.
patent: 5211952 (1993-05-01), Spicer et al.
patent: 5223261 (1993-06-01), Nelson et al.
patent: 5340584 (1994-08-01), Spicer et al.
patent: 5340585 (1994-08-01), Pike et al.
patent: 5340586 (1994-08-01), Pike et al.
patent: 5468736 (1995-11-01), Hodgen
patent: 5633242 (1997-05-01), Oettel et al.
patent: 5662927 (1997-09-01), Ehrlich et al.
patent: 5827843 (1998-10-01), Koninckx
patent: 6214815 (2001-04-01), Shangold et al.
patent: 6500814 (2002-12-01), Hesch
patent: 2002/0183299 (2002-12-01), Voskuhl
patent: 2336433 (1975-04-01), None
patent: 2336434 (1975-04-01), None
patent: 2426779 (1975-12-01), None
patent: 199 17 930 (2000-10-01), None
patent: 0402950 (1975-12-01), None
patent: 468690 (1991-07-01), None
patent: 1700602 (2001-05-01), None
patent: 9603929 (1966-02-01), None
patent: 9218107 (1992-10-01), None
patent: 9426207 (1994-11-01), None
patent: 9502408 (1995-01-01), None
patent: WO 95/17895 (1995-07-01), None
patent: WO 9603929 (1996-02-01), None
patent: 9858657 (1998-12-01), None
patent: 0062753 (2000-10-01), None
patent: WO 00/73416 (2000-12-01), None
patent: 0130357 (2001-05-01), None
patent: WO 01/85154 (2001-11-01), None
Erdbruegger et al. Drug Discovery Today: Disease Mechanisms (2004), vol. 1, 73-81.
Lab Tests Online (www.labtestsonline.org/understanding/conditions/autoimmune.html) retrived on Aug. 3, 2007.
www.tiscali.co.uk/lifestyle/healthfitness/health—advice
etdoctor/archive/000489.html.
MedlinePlus Medical Encyclopedia: Multiple Sclerosis, retrieved on Mar. 28, 2008 via www.nlm.nih.gov/medlineplus/ency/article/000737.htm, dated on Aug. 6, 2007.
WebMD: Multiple Sclerosis—Prevention, retrieved on Mar. 28, 2008 via www.webmd.com/multiple-sclerosis/tc/multiple-sclerosisms-prevention, dated on Mar. 23, 2006.
MedlinePlus Medical Encyclopedia: rheumatoid arthritis, retrieved on Mar. 28, 2008 via www.nlm.nih.gov/medlineplus/ency/article/000431.htm, dated on Jul. 27, 2007.
WebMD: Rheumatoid Arthritis—Prevention, retrieved on Mar. 28, 2008 via www.webmd.com/rheumatoid-arthritis/tc/rheumatoid-arthritis-prevention, dated on Aug. 23, 2006.
Prophylactic definition—Medical Dictionary of Popular Medical Terms: retrieved on Mar. 14, 2008 via www.medterms.com/script/main/art.asp?articlekey=11902.
MedlinePlus Medical Encyclopedia: Multiple Sclerosis, retrieved on Mar. 28, 2008 via www.nlm.nih.gov/medlineplus/ency/article/000737.htm, dated on Aug. 6, 2007, p. 1 and 2.
MedlinePlus Medical Encyclopedia: Multiple Sclerosis, retrieved on Mar. 28, 2008, p. 2; also see WebMD: Multiple Sclerosis—Prevention, retrieved on Mar. 28, 2008 via www.webmd.com/multiple-sclerosis/tc/multiple-sclerosis-ms-prevention, dated on Mar. 23, 2006.
MedlinePlus Medical Encyclopedia: rheumatoid arthritis, retrieved on Mar. 28, 2008 via www.nlm.nih.gov/medlineplus/ency/article/000431.htm, dated on Jul. 27, 2007, p. 1-2 and 4; also WebMD: Rheumatoid Arthritis—Prevention, retrieved on Mar. 28, 2008 via www.webmd.com/rheumatoid-arthritis/tc/rheumatoid-arthritis-prevention, dated on Aug. 23, 2006.
Levine et al. (Am. J. Obstet. Gynecol. Mar. 15, 1984, p. 735-738).
Allen et al., An Ovarian Hormone: Preliminary Report on Its Localization, Extraction and Partial Purification, and Action In Test Animals, JAMA, Sep. 8, 1923, vol. 81, pp. 819-821.
Allen et al., The Induction of a Sexually Mature Condition in Immature Females by Injection of the Ovarian Follicular Hormone, Am. J. Physiol., 1924, vol. 69, pp. 577-588.
Fishman, Fate of 15a-Hydroxyestriol-3H in Adult Man, J. Clin. Endocrinol. Metab., 1970, vol. 31, pp. 436-438.
Jones et al., The Effects of Various Steroids on the Vaginal Histology in the Rat, Fertility and Sterility, Apr. 1973, vol. 24, No. 4, pp. 284-291.
Tulchinsky et al., Plasma Esterol as an Index of Fetal Well-Being, J. Clin. Endrocrinol. Metab., 1975, vol. 40. pp. 560-567.
Tseng et al., Competition of Esterol and Ethynylestradiol with Estradiol for Nuclear Binding in Human Endometrium, Journal of Steroid Biochemistry, 1976, vol. 7, pp. 817-822.
Martucci et al., Uterine Estrogen Receptor Binding of Cathecholestrogens and of Esterol (1,2,5(10)-Estratriene-3,15a,16a,17 β-Tetrol), Steroids, Mar. 1976, vol. 27, No. 3, pp. 325-333.
Martucci et al., Direction of Estradiol Metabolism as a Control of its Hormonal Action—Uterotrophic Activity of Estradiol Metabolites, Endrocrin., 1977, vol. 101, pp. 1709-1715.
Tseng et al., Heterogeneity of Saturable Estradiol Binding Sites in Nuclei of Human Endometrium Esterol Studies, Steroid Biochem., 1978, vol. 9, pp. 1145-1148.
Holinka et al., “in Vivo Effects of Esterol on the Immature Rat Uterus”, Biology of Reproduction, Society for the Reproduction Society for the Study of Reproduction, Champaign, IL, US, Mar. 1979, vol. 20, No. 2, pp. 242-246.
Holinka, et al., “Comparison of Effects of Esterol and Tamoxifen with Those of Estriol and Estradiol on the Immature Rat Uterus”, Biology of Reproduction, Society for the Reproduction Society for the Study of Reproduction, Champaign, IL, US, 1980, vol. 22, No. 4, pp. 913-926.
Jozan et al., Different Effects of Oestradiol, Oestriol, Oestrol and of Oestrone on Human Breast Cancer Cells (MCF-7) in Long Term Tissue Culture, Acta Endocrinologica, 1981, vol. 98, pp. 73-80.
Hammond et al., A Versatile Method for the Determination of Serum Cortisol Binding Globulin and Sex Hormone Binding Globulin Binding Capacities, 1983, vol. 132, pp. 101-110.
Levine et al., Uterine Vascular Effects of Esterol in Nonpregnant Ewes, Am. J. Obstet. Gynecol., 1984, vol. 148, No. 73. pp. 735-738.
Jansson et al., “Estrogen Induces a Potent Suppression of Experimental Autoimmune Encephalomyelitis and Collagen-Induced Arthritis in Mice”, Journal of Neuroimmunology, Elsevier Science Publishers BV XX, 1994, vol. 53, No. 2, pp. 203-207.
Elger et al., Sulfamates of Various Estrogens are Prodrugs with Increased Systemic and Reduced Hepatic Estrogenicity at Oral Application, J. Steroid Biochem. Molec. Biol., 1995, vol. 55, No. 3 / 4, pp. 395-403.
Murphy et al., Endometrial Effects of Long-Term Low-Dose Administration of RU486, Fertility and Sterility, Apr. 1995, vol. 63, No. 4, pp. 761-766.
Reel et al., Survey and Assessment of Mammalian Estrogen Biological Assays for Hazard Characterization, Fundamental and Applied Toxicology, 1996, vol. 34, pp. 288-305.
Beral et al., Use of HRT and the Subsequent Risk of Cancer, Journal of Epidemiology and Biostatistics, 1999, vol. 4, No. 3, pp. 191-215.
Tavani et al., The Adverse Effects of Hormone Replacement Therapy, Drugs & Aging, May 1999, vol. 14, No. 5, pp. 347-357.
Pike et al., Progestins and Menopause: Epidemiological Studies of Risks of Endometrial and Breast Cancer, S
Bennink Herman Jan Tijmen Coelingh
Bunschoten Evert Johannes
Holinka Christian Franz
Chui Mei-Ping
Padmanabhan Sreeni
Pantarhei Bioscience B.V.
The Webb Law Firm
LandOfFree
Method of treating or preventing immune mediated disorders... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating or preventing immune mediated disorders..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating or preventing immune mediated disorders... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2648573